Jaguar Health Inc surges amid market gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 Jan 26
Source: PRE 14A
Jaguar Health Inc's stock price increased by 42.58% in pre-market trading as it crossed above the 5-day SMA, reflecting strong investor interest.
The surge in Jaguar Health's stock is attributed to broad market strength, with both the Nasdaq-100 and S&P 500 showing positive movements of 0.46% and 0.28%, respectively. This favorable market environment has likely contributed to the heightened demand for Jaguar Health shares.
This significant price movement may indicate growing confidence among investors in Jaguar Health's future prospects, potentially leading to increased trading volume and interest in the company's developments.
Analyst Views on JAGX
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
